Physician profile
Ali Rahim
NPI 1114556347
$959.55
in general payments reported to CMS, 2019-2025
13 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $99.90 · 2024: $303 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $386.11 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $98.49 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $96.91 | 2025 | |
| Phathom Pharmaceuticals, INC. | $71.45 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $54.69 | 2025 | Trelegy Ellipta |
| Lilly USA, LLC | $53.59 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $46.05 | 2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $39.89 | 2023 | |
| Abbott Laboratories | $30.59 | 2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $28.16 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.20 | 2024 | Jardiance |
| Pfizer INC. | $18.17 | 2025 | |
| Novo Nordisk INC | $15.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Rahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.